TransEnterix Announces Toshima Hospital in Japan to Initiate a Senhance® Digital Laparoscopy Program
07 Octubre 2020 - 5:55AM
Business Wire
Japan is One of the Fastest Growing Markets for
Senhance Surgical System
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that the Toshima Hospital of the Tokyo Metropolitan Health and
Hospitals Corporation has entered into an agreement to lease and
utilize a Senhance® Surgical System.
“We are excited to partner with Toshima Hospital to build its
Senhance Digital Laparoscopy Program,” said Anthony Fernando,
President and Chief Executive Officer at TransEnterix. “Japan has
become one of the fastest growing markets for Senhance in terms of
both placements and clinical cases given our attractive per
procedure economics, comprehensive reimbursement coverage and
ability to add digital capabilities to the strong foundation of
laparoscopy. Our recently inaugurated training center in Japan will
further accelerate our growth in the region.”
Toshima Hospital is a comprehensive inpatient and outpatient
facility with 415 inpatient beds, and is affiliated with the Tokyo
Medical and Dental University. The hospital is part of the six
hospital network operated by the Tokyo Metropolitan Health and
Hospitals Corporation to provide excellence in healthcare and
promote the welfare of the citizens of the Tokyo metro area.
“Our hospital is dedicated to offering the best possible
surgical care that is part of a comprehensive program for the
members of our community,” said Dr. Masayuki Ando, Director of
Toshima Hospital and Clinical Professor of Surgery at Tokyo Medical
and Dental University. “We are committed to utilizing the most
advanced technology where we feel it can positively impact our
ability to care for our patients. The Senhance SURGICAL System is
an advanced minimally invasive surgical tool that our surgeons will
utilize to offer excellent advanced surgery at a reasonable
cost.”
“Advanced minimally invasive surgery requires precision,
superior visualization, and advanced instrumentation,” said Dr.
Yusuke Kinugasa, Chairman of Colorectal and Proctology Surgery at
Tokyo Medical and Dental University. “We selected the Senhance
Surgical System because of its ability to build upon our excellent
laparoscopic surgery program and add advanced visualization and
digital capabilities.”
The Senhance Surgical System is the first and only digital
laparoscopic platform designed to maintain laparoscopic minimally
invasive surgical standards while providing digital benefits such
as haptic feedback, robotic precision, eye-sensing camera control,
comfortable ergonomics, advanced instrumentation including, 3 mm
microlaparoscopic instruments, and reusable standard instruments to
help maintaining per-procedure costs similar to traditional
laparoscopy. The Senhance Surgical System was approved for use by
the Japanese Ministry of Health, Labor and Welfare (MHLW) in 2019,
and has the broadest procedural reimbursement of any abdominal
robotic surgery platform in Japan, which applies to 98 benign and
malignant laparoscopic procedures across general, colorectal,
gynecologic, pediatric and urologic surgeries at reimbursement
rates equivalent to traditional laparoscopy in Category A1.
Japan is the second-largest medical device market in the world,
valued at over $40 billion annually, including over $5 billion in
capital equipment spending. There are more than 8,400 hospitals in
Japan, of which approximately 80% are private entities. Japanese
laparoscopic penetration in surgery is among the highest in the
world. The central government has implemented cost containment
initiatives in recent years and has approached recent procedure
approvals for robotics by establishing reimbursement at the same
rate as traditional laparoscopy, which places a high emphasis on
procedure cost to influence adoption.
About TransEnterix
At TransEnterix, Inc., we are digitizing the interface between
the surgeon and the patient to improve minimally invasive surgery
(MIS) through a new category of care called Digital Laparoscopy.
Digitizing the interface enables the use of advanced capabilities
like augmented intelligence, connectivity and robotics in
laparoscopy, and allows us to address the current clinical,
cognitive and economic shortcomings in surgery. The system features
the first machine vision system for use in robotic surgery which is
powered by the new Intelligent Surgical Unit™ (ISU™) that enables
augmented intelligence in surgery. The Senhance®️ Surgical System
brings the benefits of Digital Laparoscopy to patients around the
world while staying true to the principles of value-based
healthcare. Learn more about Digital Laparoscopy with the Senhance
Surgical System here: https://Senhance.com/. Now available for sale
in the US, the EU, Japan, and select other countries. For a
complete list of indications for use, please visit:
https://www.transenterix.com/indications-for-use/.
Forward-Looking Statements
This press release includes statements relating to the Senhance
System and the Toshima Hospital initiating a program for the
Senhance System. These statements and other statements regarding
our future plans and goals constitute "forward looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and are
intended to qualify for the safe harbor from liability established
by the Private Securities Litigation Reform Act of 1995. Such
statements are subject to risks and uncertainties that are often
difficult to predict, are beyond our control and which may cause
results to differ materially from expectations and include whether
Japan will continue to be one of the fastest growing markets for
the Senhance System in both placements and clinical cases, whether
our recently inaugurated training center in Japan will further
accelerate our growth in the region and whether the Toshima
Hospital surgeons will utilize the Senhance System to offer
excellent advanced surgery at a reasonable cost. For a discussion
of the risks and uncertainties associated with TransEnterix's
business, please review our filings with the Securities and
Exchange Commission (SEC), including our Annual Report on Form 10-K
for the year ended December 31, 2019, filed with the SEC on March
16, 2020 and our other filings we make with the SEC. You are
cautioned not to place undue reliance on these forward looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the origination date of
this press release. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201007005221/en/
For TransEnterix, Inc. Investor Contact: Mark Klausner, +1
443-213-0501 invest@transenterix.com or Media Contact: Terri
Clevenger, +1 203-682-8297 terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024